Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease

Research output: Contribution to journalArticle

Standard

Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease. / Tedroff, Joakim; Waters, Susanna; Barker, Roger A; Roos, Raymund; Squitieri, Ferdinando; EHDN Registry Study Group.

In: Journal of Huntington's disease, Vol. 4, No. 2, 2015, p. 131-40.

Research output: Contribution to journalArticle

Harvard

Tedroff, J, Waters, S, Barker, RA, Roos, R, Squitieri, F & EHDN Registry Study Group 2015, 'Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease', Journal of Huntington's disease, vol. 4, no. 2, pp. 131-40. https://doi.org/10.3233/JHD-150143

APA

Tedroff, J., Waters, S., Barker, R. A., Roos, R., Squitieri, F., & EHDN Registry Study Group (2015). Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease. Journal of Huntington's disease, 4(2), 131-40. https://doi.org/10.3233/JHD-150143

CBE

MLA

Vancouver

Author

Tedroff, Joakim ; Waters, Susanna ; Barker, Roger A ; Roos, Raymund ; Squitieri, Ferdinando ; EHDN Registry Study Group. / Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease. In: Journal of Huntington's disease. 2015 ; Vol. 4, No. 2. pp. 131-40.

RIS

TY - JOUR

T1 - Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease

AU - Tedroff, Joakim

AU - Waters, Susanna

AU - Barker, Roger A

AU - Roos, Raymund

AU - Squitieri, Ferdinando

AU - EHDN Registry Study Group

PY - 2015

Y1 - 2015

N2 - BACKGROUND: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder leading to progressive motor, cognitive and functional decline. Antidopaminergic medications (ADMs) are frequently used to treat chorea and behavioural disturbances in HD.OBJECTIVE: We aimed to assess how the use of such medications was associated with the severity and progression of the motor aspects of the condition, given that there have been concerns that such drugs may actually promote neurological deterioration.METHODS: Using multiple linear regression, supplemented by principal component analysis to explore the overall correlation patterns and help identify relevant covariates, we assessed severity and progression of motor symptoms and functional decline in 651 manifest patients from the REGISTRY cohort followed for two years. ADM treated versus non-treated subjects were compared with respect to motor impairment at baseline and progression rate by means of multiple regression, adjusting for CAG-repeat and age.RESULTS: Patients treated with ADMs had significantly worse motor scores with greater functional disability at their first visit. They also showed a higher annual rate of progression of motor signs and disability over the next two years. In particular the rate of progression for oculomotor symptoms and bradykinesia was markedly increased whereas the rate of progression of chorea and dystonia was similar for ADM and drug naïve patients. These differences in clinical severity and progression could not be explained by differences in disease burden, duration of disease or other possible prognostic factors.CONCLUSIONS: The results from this analysis suggest ADM treatment is associated with more advanced and rapidly progressing HD although whether these drugs are causative in driving this progression requires further, prospective studies.

AB - BACKGROUND: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder leading to progressive motor, cognitive and functional decline. Antidopaminergic medications (ADMs) are frequently used to treat chorea and behavioural disturbances in HD.OBJECTIVE: We aimed to assess how the use of such medications was associated with the severity and progression of the motor aspects of the condition, given that there have been concerns that such drugs may actually promote neurological deterioration.METHODS: Using multiple linear regression, supplemented by principal component analysis to explore the overall correlation patterns and help identify relevant covariates, we assessed severity and progression of motor symptoms and functional decline in 651 manifest patients from the REGISTRY cohort followed for two years. ADM treated versus non-treated subjects were compared with respect to motor impairment at baseline and progression rate by means of multiple regression, adjusting for CAG-repeat and age.RESULTS: Patients treated with ADMs had significantly worse motor scores with greater functional disability at their first visit. They also showed a higher annual rate of progression of motor signs and disability over the next two years. In particular the rate of progression for oculomotor symptoms and bradykinesia was markedly increased whereas the rate of progression of chorea and dystonia was similar for ADM and drug naïve patients. These differences in clinical severity and progression could not be explained by differences in disease burden, duration of disease or other possible prognostic factors.CONCLUSIONS: The results from this analysis suggest ADM treatment is associated with more advanced and rapidly progressing HD although whether these drugs are causative in driving this progression requires further, prospective studies.

KW - Adult

KW - Antipsychotic Agents

KW - Disease Progression

KW - Dopamine Agents

KW - Female

KW - Humans

KW - Huntington Disease

KW - Linear Models

KW - Male

KW - Middle Aged

KW - Motor Activity

KW - Principal Component Analysis

KW - Registries

KW - Journal Article

U2 - 10.3233/JHD-150143

DO - 10.3233/JHD-150143

M3 - Article

VL - 4

SP - 131

EP - 140

JO - Journal of Huntington's disease

JF - Journal of Huntington's disease

SN - 1879-6397

IS - 2

ER -